NO20061252L - Doseringsplan for ERBB2 antikreftmidler - Google Patents
Doseringsplan for ERBB2 antikreftmidlerInfo
- Publication number
- NO20061252L NO20061252L NO20061252A NO20061252A NO20061252L NO 20061252 L NO20061252 L NO 20061252L NO 20061252 A NO20061252 A NO 20061252A NO 20061252 A NO20061252 A NO 20061252A NO 20061252 L NO20061252 L NO 20061252L
- Authority
- NO
- Norway
- Prior art keywords
- erbb2
- mammal
- inhibitor
- anticancer agents
- dosage schedule
- Prior art date
Links
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 230000002018 overexpression Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49591903P | 2003-08-18 | 2003-08-18 | |
PCT/IB2004/002580 WO2005016347A1 (en) | 2003-08-18 | 2004-08-06 | Dosing schedule for erbb2 anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061252L true NO20061252L (no) | 2006-05-16 |
Family
ID=34193358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061252A NO20061252L (no) | 2003-08-18 | 2006-03-17 | Doseringsplan for ERBB2 antikreftmidler |
Country Status (18)
Country | Link |
---|---|
US (1) | US20050119288A1 (pt) |
EP (1) | EP1658080A1 (pt) |
JP (1) | JP2007502807A (pt) |
KR (2) | KR20060037447A (pt) |
CN (1) | CN1838959A (pt) |
AR (1) | AR045268A1 (pt) |
AU (1) | AU2004264726A1 (pt) |
BR (1) | BRPI0413745A (pt) |
CA (1) | CA2536140A1 (pt) |
CO (1) | CO5670356A2 (pt) |
IL (1) | IL173127A0 (pt) |
MX (1) | MXPA06001989A (pt) |
NO (1) | NO20061252L (pt) |
RU (1) | RU2328287C2 (pt) |
SG (1) | SG135193A1 (pt) |
TW (1) | TW200522966A (pt) |
WO (1) | WO2005016347A1 (pt) |
ZA (1) | ZA200600517B (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008379B1 (ru) | 2002-02-01 | 2007-04-27 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их применения |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
CA2535614C (en) * | 2003-08-14 | 2009-12-22 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
SI1667992T1 (sl) | 2003-09-19 | 2007-06-30 | Astrazeneca Ab | Kinazolinski derivati |
AU2005239878B9 (en) | 2004-05-06 | 2010-01-07 | Warner-Lambert Company Llc | 4-phenylamino-quinazolin-6-yl-amides |
GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
EP1896030A1 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
NZ562109A (en) * | 2005-06-16 | 2011-03-31 | Myrexis Inc | Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same |
WO2007014335A2 (en) * | 2005-07-27 | 2007-02-01 | The University Of Texas System | Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer |
US8945573B2 (en) * | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
JP5709354B2 (ja) * | 2005-11-14 | 2015-04-30 | アリアド・ファーマシューティカルズ・インコーポレイテッド | mTOR阻害剤投与によるがん患者の治療 |
PL1971601T3 (pl) * | 2005-11-15 | 2010-03-31 | Array Biopharma Inc | Pochodne N4-fenylo-chinazolino-4-aminy i związki pokrewne jako inhibitory receptorowych kinaz tyrozynowych ErbB typu I do leczenia chorób cechujących się nadmierną proliferacją komórek |
US20070274991A1 (en) * | 2006-03-31 | 2007-11-29 | Way Jeffrey C | Treatment of tumors expressing mutant EGF receptors |
MX2008012716A (es) * | 2006-04-05 | 2008-10-14 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento de cancer. |
CN103330694A (zh) | 2006-11-14 | 2013-10-02 | 阿里亚德医药股份有限公司 | 口服制剂 |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
WO2008124826A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating cancer |
AU2008236994A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating melanoma |
NZ580868A (en) * | 2007-04-10 | 2011-07-29 | Myriad Pharmaceuticals Inc | Dosages and methods for the treatment of cancer |
KR20100016385A (ko) * | 2007-04-10 | 2010-02-12 | 미리어드 파마슈티칼스, 인코포레이티드 | 뇌종양 치료방법 |
EP2171090B1 (en) * | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
WO2009137714A2 (en) * | 2008-05-07 | 2009-11-12 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
US20100087459A1 (en) * | 2008-08-26 | 2010-04-08 | Leonid Metsger | Forms of lapatinib compounds and processes for the preparation thereof |
MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
WO2013078440A2 (en) * | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
JP6183471B2 (ja) * | 2014-01-31 | 2017-08-23 | 凸版印刷株式会社 | 生体分子解析キット及び生体分子解析方法 |
EP3368546A4 (en) * | 2015-10-28 | 2019-06-26 | Tarveda Therapeutics, Inc. | SSTR TARGETED CONJUGATES, AND ITS PARTICLES AND FORMULATIONS |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02012870A (es) * | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal. |
EP1465632A1 (en) * | 2001-12-12 | 2004-10-13 | Pfizer Products Inc. | Quinazoline derivatives for the treatment of abnormal cell growth |
PL370858A1 (en) * | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
EP1567506A4 (en) * | 2002-11-20 | 2007-06-20 | Array Biopharma Inc | CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR |
MXPA05006335A (es) * | 2002-12-18 | 2005-08-26 | Pfizer Prod Inc | Derivados biciclicos para el tratamiento del crecimiento celular anormal. |
-
2004
- 2004-08-06 MX MXPA06001989A patent/MXPA06001989A/es not_active Application Discontinuation
- 2004-08-06 BR BRPI0413745-0A patent/BRPI0413745A/pt not_active IP Right Cessation
- 2004-08-06 RU RU2006102125/14A patent/RU2328287C2/ru not_active IP Right Cessation
- 2004-08-06 WO PCT/IB2004/002580 patent/WO2005016347A1/en active Application Filing
- 2004-08-06 CA CA002536140A patent/CA2536140A1/en not_active Abandoned
- 2004-08-06 CN CNA200480023705XA patent/CN1838959A/zh active Pending
- 2004-08-06 JP JP2006523695A patent/JP2007502807A/ja not_active Withdrawn
- 2004-08-06 EP EP04744217A patent/EP1658080A1/en not_active Withdrawn
- 2004-08-06 KR KR1020067003190A patent/KR20060037447A/ko not_active Application Discontinuation
- 2004-08-06 KR KR1020087000092A patent/KR20080014144A/ko not_active Application Discontinuation
- 2004-08-06 SG SG200706063-5A patent/SG135193A1/en unknown
- 2004-08-06 AU AU2004264726A patent/AU2004264726A1/en not_active Abandoned
- 2004-08-17 AR ARP040102941A patent/AR045268A1/es not_active Application Discontinuation
- 2004-08-17 TW TW093124706A patent/TW200522966A/zh unknown
- 2004-08-17 US US10/919,831 patent/US20050119288A1/en not_active Abandoned
-
2006
- 2006-01-12 IL IL173127A patent/IL173127A0/en unknown
- 2006-01-18 ZA ZA200600517A patent/ZA200600517B/xx unknown
- 2006-02-15 CO CO06015089A patent/CO5670356A2/es not_active Application Discontinuation
- 2006-03-17 NO NO20061252A patent/NO20061252L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007502807A (ja) | 2007-02-15 |
IL173127A0 (en) | 2006-06-11 |
BRPI0413745A (pt) | 2006-10-24 |
US20050119288A1 (en) | 2005-06-02 |
EP1658080A1 (en) | 2006-05-24 |
CA2536140A1 (en) | 2005-02-24 |
CO5670356A2 (es) | 2006-08-31 |
RU2328287C2 (ru) | 2008-07-10 |
MXPA06001989A (es) | 2006-05-17 |
KR20080014144A (ko) | 2008-02-13 |
AR045268A1 (es) | 2005-10-19 |
ZA200600517B (en) | 2007-02-28 |
SG135193A1 (en) | 2007-09-28 |
WO2005016347A1 (en) | 2005-02-24 |
TW200522966A (en) | 2005-07-16 |
KR20060037447A (ko) | 2006-05-03 |
AU2004264726A1 (en) | 2005-02-24 |
CN1838959A (zh) | 2006-09-27 |
RU2006102125A (ru) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061252L (no) | Doseringsplan for ERBB2 antikreftmidler | |
ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
NO20050204L (no) | Kombinasjoner av legemidler for behandling av neoplasmer | |
RU2010133480A (ru) | Лечение метастатической стадии рака предстательной железы дегареликсом | |
RU2012111823A (ru) | Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы | |
AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
WO2009044392A3 (en) | Novel sirna structures | |
MY169275A (en) | Method of immunization against the four serotypes of dengue | |
DK2437749T3 (da) | Kombineret fremgangsmåde til behandling af kræft eller en præcancerøs tilstand | |
BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
TW200639159A (en) | Treatment of pain | |
UA81625C2 (ru) | Применение ротиготина для трансепикутального лечения синдрома уставших ног | |
MX2007004955A (es) | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. | |
MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
IL307516A (en) | Tremor treatment | |
TW200719903A (en) | Compositions for the treatment of neoplasms | |
FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
MX2010002679A (es) | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. | |
TW200635609A (en) | Novel pharmaceutical composition containing at least one dolastatin 10 derivative | |
MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
HK1085744A1 (en) | Steroid compounds with anti-tumor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |